Canada: Error In Registering Trade-Mark Must Be Corrected Via Section 57 Of The "Trade-Marks Act" (Intellectual Property Weekly Abstracts Bulletin: Week Of December 16, 2013)

Last Updated: December 19 2013

Edited by Chantal Saunders and Beverley Moore and Adrian Howard

TRADE-MARKS

Error in Registering Trade-mark Must be Corrected via Section 57 of the Trade-marks Act

299614 Alberta Ltd. v. Fresh Hemp Foods Ltd., 2013 FC 1245

The Registrar of Trade-marks (Registrar) allowed the trade-mark application by Fresh Hemp Foods. 299614 Alberta (the Applicant) appealed the decision pursuant to section 56(1) of the Trade-marks Act.

The Court held that it was clear that the registration was allowed because the Registrar erroneously thought the opposition to the registration had been withdrawn. Although the Court found that Fresh Hemp Foods was granted rights that it would not otherwise have had because of this error, the Court held that the correct way to proceed is to commence expungement proceedings pursuant to section 57, and not an appeal pursuant to section 56. Accordingly, the application was dismissed.

Palpable and Overriding Error Found by Court of Appeal in Considering New Evidence to be Material

Kelly Properties v. Canadian Council of Professional Engineers, 2013 FCA 287

The Court found that additional evidence provided by the Respondents would have materially affected the outcome at the Trade-marks Opposition Board (Board). The Court of Appeal held that the Court committed a palpable and overriding error in making this finding. In particular, the Court of Appeal found that the evidence of two witnesses about the interpretation of the Engineering and Geoscience Professions Act was irrelevant, the additional affidavits added no new material facts compared to what was before the Board, and the Board's decision was not unreasonable. The appeal was allowed.

NOC PROCEEDINGS

Court of Appeal Confirms that Subsequent Declaration of Invalidity does not Vary Order of Prohibition

Apotex Inc. v. Eli Lilly Canada Inc., 2013 FCA 282

The issue to be determined by the Court of Appeal in this appeal was whether an Order of prohibition in a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations can be varied pursuant to Rule 399 of the Federal Courts Rules, as a result of a declaration of invalidity in a subsequent proceeding. The Court dismissed the motion, and Apotex appealed the finding.

The Court of Appeal noted that, in an unrelated proceeding, the Court of Appeal previously has held that an order of prohibition does not get set aside when a patent is declared invalid, and that Apotex must convince the Court of Appeal that this decision is manifestly wrong in order to succeed.

The Court of Appeal held that they were not persuaded that the Court committed a reviewable error but noted that arguments to the effect that prior decisions are bad law are better addressed through an application for leave to appeal to the Supreme Court of Canada.

Fact-specific Issues Relevant to Calculating Section 8 Damages are Decided

Apotex Inc. v. Takeda Canada Inc., 2013 FC 1237

This decision provides answers to certain issues that would allow the parties to calculate the loss under section 8 of the PM(NOC) Regulations that arose from an earlier decision of the Federal Court. In that earlier decision, Apotex's allegations of non-infringement for the product pantoprazole were found to be justified.

The issues left to be resolved in this proceeding included: 1) the burden of proof; 2) the number and identity of generic market entrants; 3) market share; 4) price; 5) inventory adjustment; 6) double ramp-up; 7) rebates; 8) interest; and 9) discretion to reduce the award based on Apotex's misconduct.

This was a highly fact-based exercise, but the Court did decide to not deduct the "ramp up" period at the start of the relevant period because a "ramp up" was experienced by Apotex in the real world. In distinguishing precedent, the Court considered that adding it in a second time was seen as doubling the ramp up to the detriment of the generic company.

Prejudgment interest was calculated from the quarter proceeding the date the Apotex sent their statement of claim, calculated from the patent hold date.

Takeda had argued that the award should be reduced by Apotex's alleged breach of undertaking. In the NOA, Apotex had stated that "[e]ach of the claims of the '748 Patent includes as an essential element a Helicobacter-inhibiting anti-microbial agent. Our sodium pantoprazole tablets shall not contain said agent, as that term is construed in accordance with the claims of the '748 Patent, nor shall our tablets be marketed or promoted to doctors, pharmacists or others to be used in combination with a Helicobacter-inhibiting anti-microbial agent or as part of a medicament package comprising said agent. As such, our tablets shall not infringe any of the claims of the '748 patent."

The Court declined to find that the allegation within Apotex's NOA rose to the level of an undertaking to be relied upon by the Court. Therefore, the fact that Apotex took no steps to prevent the marketing and promoting of their product for the treatment of Helicobacter pylori was of no consequence.

OTHER NEWS

Health Canada has published a number of new and updated forms: Notice – Post- Notice of Compliance (NOC) Changes: Notices of Change (Level III) Form; Drug Master File (DMF) Application Form; Health Canada 3011: Drug Submission Application Form for Human, Veterinary, Disinfectant Drugs and Clinical Trial Application/Attestation; and Clinical Trials Site Information Form.

Health Canada has started a Consultation – Data requirements for switching medicinal ingredients from prescription to non-prescription status.

The PMPRB has released two new analytical reports under the National Prescription Drug Utilization Information System (NPDUIS) Initiative: The Drivers of Prescription Drug Expenditures – A Methodological Report and The New Drug Pipeline Monitor (5th Ed).

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions